Nektar Therapeutics Investor Presentation — November 2019

Document content

Jefferies 2019 London

Healthcare Conference

Jonathan Zalevsky, PhD

November 20, 20192This presentation includes forward -looking statements regarding Nektar’s proprietary drug

candidates, the timing of the start and conclusion of ongoing or planned clinical trials, the timing

and outcome of regulatory decisions, and future availability of clinical trial data. Actual results

could differ materially and these statements are subject to important risks detailed in Nektar's

filings with the SEC including the Form 10 -Q filed on November 7, 2019. Nektar undertakes no

obligation to update forward -looking statements as a result of new information or otherwise.3

Focus of Nektar Pipeline

Target the innate and

adaptive immune systemImmuno -oncology

NKTR -255 (Wholly -Owned)

IL-15 Receptor Agonist

Phase 1 First- in-Human Study in

NHL and MM Initiated Oct 2019

(Co-Develop and Co -Promote)

CD122 -preferential IL -2

Multiple Solid Tumors

NKTR -262 (Wholly -Owned)

Multiple Solid Tumors

Phase 1/2 study ongoingA next generation opioid

molecule Chronic Pain

NKTR -181 (Wholly -Owned)

Chronic Low Back Pain

Awaiting product -specific

advisory committeeHarness the immune

system to fight auto -

immune disease Immunology

NKTR -358 (Co-Promote)

Preview truncated — download the full document for the complete content.